396 related articles for article (PubMed ID: 26590165)
1. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
2. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
3. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
7. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
8. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
9. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
10. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
11. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
Herviou L; Cavalli G; Moreaux J
Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
[TBL] [Abstract][Full Text] [Related]
12. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
17. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
[TBL] [Abstract][Full Text] [Related]
18. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
19. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
20. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
